Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature

Abstract Background Nivolumab is an immune checkpoint inhibitor targeting programmed death-1 protein and has been approved for the treatment of multiple advanced malignancies. Adverse effects of immune checkpoint inhibitors are distinct from conventional cytotoxic chemotherapy and can be life-threat...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Shagufta Shaheen, Hamid Mirshahidi, Gayathri Nagaraj, Chung-Tsen Hsueh
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BMC 2018-05-01
Cyfres:Experimental Hematology & Oncology
Pynciau:
Non-small cell lung cancer
Immune checkpoint inhibitor
Nivolumab
Pericardial effusion
Corticosteroids
Mynediad Ar-lein:http://link.springer.com/article/10.1186/s40164-018-0104-y
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg